The headlines may have faded, but the Nitrosamine contamination saga continues. With all European Medicines Agency Marketing Authorization Holders (MAH) now obligated to evaluate the risks of their products containing chemically synthesized APIs, choosing a partner you can trust has never been more important.

‍

‍

Here at QUINTA-ANALYTICA we have developed versatile proprietary ULPC/MS/MS methods for quantitative determination of Nitrosamines under full #GMP conditions, and with the capability of reaching LOQ down to 20 ppb. Our dedicated and cross-functional Nitrosamine team is perfectly placed to meet your needs and secure delivery of test results accurately, professionally, and within the agreed time-frame.

Read more about the types of Nitrosamines and matrixes that our testing has already been proven on, and learn more about our testing processes on our webpage devoted to Nitrosamines.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

ALL POSTS